Diagnostics company Meridian Bioscience (NASDAQ: VIVO) has received federal regulatory clearance to begin selling a pediatric version of its C. difficile test. An earlier version of the test, which the company calls the "illumigene," was cleared for commercialization by the FDA in July. However, that clearance didn't apply to children.
Life science diagnostic testing company Meridian Bioscience had a strong 2010 as swine flu fears pushed up demand for its rapid flu tests. But without swine flu, Meridian announced a 32 percent decrease in the diagnostic test maker's first-quarter earnings for fiscal 2011.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
It happened to diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO), but at least it doesn't appear to have caused any damage. Meridian was victimized by a Twitter "name squatter." That is, someone not affiliated with the company created a Twitter account using its name, logo and references to its website.
Diagnostic test maker Meridian Bioscience Inc. (NASDAQ:VIVO) capped a "disappointing" fiscal 2010 with fourth-quarter profits that fell below Wall Street's expectations and sent its shares tumbling.
Meridian Bioscience Inc. (NASDAQ:VIVO) has obtained a license to begin selling its illumigene C. difficile molecular test in Canada.
Cincinnati, Ohio life sciences company Meridian Bioscience Inc. (NASDAQ: VIVO) has acquired the outstanding capital stock of Bioline Ltd., the London, England-based maker and distributor of molecular biology reagents, for $23.3 million in cash. Meridian Bioscience also said Tuesday its profits fell 24 percent in the fiscal third quarter from a year ago, while sales […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Diagnostics company Meridian Bioscience Inc. (NASDAQ: VIVO) has received the go-ahead from the Food and Drug Administration to sell its first molecular test — illumigene C. difficile. Over the years the Cincinnati life science company has gotten good at making diagnostic test kits that detect bugs like C. difficile, which is a bacterium that can […]
Meridian Bioscience Inc. (NASDAQ: VIVO) has struck an exclusive, world-wide product development and distribution agreement with an Italian diagnostics company that is likely to open doors to new customers in Eastern Europe and Asia. The agreement with DiaSorin S.p.A. of Vercelli, Italy, is a turnabout for Cincinnati, Ohio, diagnostic kit maker Meridian, said Todd Morrow, […]
The Biotechnology Industry Organization international convention returns to Chicago this week — a nod to the importance of pharmaceutical and therapeutic companies in Midwestern states like Ohio. Drugmaking has history in Ohio. From Procter & Gamble Pharmaceuticals (NYSE: PG) in Cincinnati (sold last year to Irish drug company Warner Chilcott), to generic drugmakers Ben Venue […]